Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Decker

Showing results (21-30 of 180) with videos related to

Pageof 18
Sort By:
Trends in Pharmacological Sciences|July 2, 2025
Photoswitchable allosteric and dualsteric ligands in GPCR pharmacologySilvia Mori, Damiano Arella, Michael Decker
Biology Letters|May 16, 2019
Extension of the minimal functional unit of the RNA polymerase II CTD from yeast to mammalian cellsNilay Shah, Tim-Michael Decker, Dirk Eick
Journal of Medicinal Chemistry|August 6, 2004
Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 receptor selectivityThomas W Wittig, Michael Decker, Jochen Lehmann
Diabetes, Obesity & Metabolism|July 25, 2007
Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosisMichael Decker, Heather Hofflich, Alan N Elias
Bioorganic & Medicinal Chemistry|January 15, 2011
Probing the mid-gorge of cholinesterases with spacer-modified bivalent quinazolinimines leads to highly potent and selective butyrylcholinesterase inhibitorsXinyu Chen, Irina G Tikhonova, Michael Decker
Arzneimittel-Forschung|January 14, 2009
A new way of data interpretation for cognition tests in rats used to characterise six choline esterase inhibitors with heterocyclic nitrogen bridgehead structure. Application in Alzheimer therapyChristian Fleck, Dorothea Appenroth, Michael Decker, et al.
The Journal of Pharmacy and Pharmacology|November 19, 2013
In-vitro stability and metabolism of a tacrine-silibinin codrugKatharina Zenger, Xinyu Chen, Michael Decker, et al.
European Journal of Medicinal Chemistry|August 12, 2019
Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligandsDiego Alejandro Rodríguez-Soacha, Matthias Scheiner, Michael Decker
Bioorganic & Medicinal Chemistry Letters|March 31, 2010
Bivalent 5,8,9,13b-tetrahydro-6H-isoquino[1,2-a]isoquinolines and -isoquinolinium salts: novel heterocyclic templates for butyrylcholinesterase inhibitorsMaria Schulze, Oliver Siol, Michael Decker, et al.
Bioorganic & Medicinal Chemistry Letters|September 3, 2004
Synthesis and vasorelaxant properties of hybrid molecules out of NO-donors and the beta-receptor blocking drug propranololMichael Decker, Andreas König, Erika Glusa, et al.
Pageof 18

Showing results (21-30 of 180) with videos related to

Sort By:
Pageof 18
Trends in Pharmacological Sciences|July 2, 2025
Photoswitchable allosteric and dualsteric ligands in GPCR pharmacologySilvia Mori, Damiano Arella, Michael Decker
Biology Letters|May 16, 2019
Extension of the minimal functional unit of the RNA polymerase II CTD from yeast to mammalian cellsNilay Shah, Tim-Michael Decker, Dirk Eick
Journal of Medicinal Chemistry|August 6, 2004
Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 receptor selectivityThomas W Wittig, Michael Decker, Jochen Lehmann
Diabetes, Obesity & Metabolism|July 25, 2007
Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosisMichael Decker, Heather Hofflich, Alan N Elias
Bioorganic & Medicinal Chemistry|January 15, 2011
Probing the mid-gorge of cholinesterases with spacer-modified bivalent quinazolinimines leads to highly potent and selective butyrylcholinesterase inhibitorsXinyu Chen, Irina G Tikhonova, Michael Decker
Arzneimittel-Forschung|January 14, 2009
A new way of data interpretation for cognition tests in rats used to characterise six choline esterase inhibitors with heterocyclic nitrogen bridgehead structure. Application in Alzheimer therapyChristian Fleck, Dorothea Appenroth, Michael Decker, et al.
The Journal of Pharmacy and Pharmacology|November 19, 2013
In-vitro stability and metabolism of a tacrine-silibinin codrugKatharina Zenger, Xinyu Chen, Michael Decker, et al.
European Journal of Medicinal Chemistry|August 12, 2019
Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligandsDiego Alejandro Rodríguez-Soacha, Matthias Scheiner, Michael Decker
Bioorganic & Medicinal Chemistry Letters|March 31, 2010
Bivalent 5,8,9,13b-tetrahydro-6H-isoquino[1,2-a]isoquinolines and -isoquinolinium salts: novel heterocyclic templates for butyrylcholinesterase inhibitorsMaria Schulze, Oliver Siol, Michael Decker, et al.
Bioorganic & Medicinal Chemistry Letters|September 3, 2004
Synthesis and vasorelaxant properties of hybrid molecules out of NO-donors and the beta-receptor blocking drug propranololMichael Decker, Andreas König, Erika Glusa, et al.
Pageof 18